Who is sponsoring NCT00420732?

NCT00420732 is sponsored by NewLink Genetics Corporation.

What condition does NCT00420732 study?

NCT00420732 studies Carcinoma, Non-Small-Cell Lung.

What drugs are being tested in NCT00420732?

Interventions: HyperAcute-Lung Cancer Vaccine.

What is the status of NCT00420732?

NCT00420732 is currently TERMINATED.

Last reviewed 2020-05-26 · How we verify

A Phase II Study of Tergenpumatucel-L (HyperAcute Lung) Cancer Vaccine in Subjects With Advanced Non-Small Cell Lung Cancer Who Responded to First Line Platinum-Doublet Treatment

NCT00420732 Phase 2 TERMINATED

To determine the response rate of the administration of HyperAcute-Lung Cancer Vaccine for subjects with stage IIIB or stage IV non-small cell lung cancer who have been treated with first line platinum-doublet therapy and have responded or are considered to have stable disease.

Details

Lead sponsor	NewLink Genetics Corporation
Phase	Phase 2
Status	TERMINATED
Enrolment	6
Start date	2007-01
Completion	2014-12

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

HyperAcute-Lung Cancer Vaccine

Primary outcomes

To determine the response rate of the administration of HyperAcute® Lung (HAL) Cancer Vaccine cells by injection into subjects with stage IIIB (pleural effusion) or stage IV non-small cell lung carcinoma who have been treated with first line platinum-dou — 4 months

Countries

United States